CClinicalTrials.gg
Status unknownNCT02041026Updated Jan 20, 2014

Investigating the Effects of Probiotic Yoghurt on Reducing the Levels of Aflatoxin B1 Toxin Among the School Children in Eastern Kenya

An interventional study of probiotic yoghurt in Aflatoxicosis, sponsored by Technical University of Kenya. Status unknown at 1 site in Kenya. Open to participants aged 6 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-20.

Sponsored by Technical University of Kenya · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2014), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
6 Years to 10 Years
Sex
All
01

Study summary

We hypothesis that intake of probiotic yogurt reduces absorption of AFB1 in the gut and subsequently reduce AFM1 and aflatoxins adduct, the biomarker in human urine and blood respectively. We have demonstrated that yogurt made using weisella cibiria NN20 isolated from fermented dough made from pearl millet in eastern part of Kenya sequestered upto 42% of aflatoxin available in our invitro texts.

Read the detailed description

In both the developed and developing world, humans are continuously exposed to a plethora of environmental toxins, both in nature and as the result of anthropomorphic activity. Aflatoxin B1, one such example, is one of the most toxic substances known to man, but it is all around us and can be found in our food, and especially cereals which form over 70% of Kenya staple food.

Limiting cereal intake is not always easy, as it is one of the most plentiful and nutritious food sources in Kenya and is the primary source of dietary energy for many societies in Kenya.

We have recently discovered a novel property of lactic acid bacteria in which aflatoxin B1, is sequestered and/or detoxified by the microbes causing reduction of toxin levels in their environment. We hypothesize that sequestration of toxins in the gastrointestinal tract by ingested probiotic bacteria will cause a reduction in host toxin uptake by carrying them out of the body in the feces preventing their passage from the gastrointestinal tract into the host. Our primary objective is to test our hypothesis that consumption of a probiotic yogurt will result in decreased levels of Aflatoxin B1 in a group of school-aged children. The secondary objective is to determine the baseline levels of aflatoxin B1 in a group of school-aged children in eastern Kenya. The tertiary objective is to establish the baseline gastrointestinal microbiota of these children and how consumption of a probiotic yogurt affects the microbiota.

A class of 60 pupils from Identified primary school, approximately 7 years old, will be randomized to two groups matching ages, sex and weight. They will receive a daily 100g serving of the probiotic yogurt and a portion of local milk in between the trial period. Before the first administration of the yogurt/milk, blood, urine and feces will be collected. After 30 days; biological specimens will again be collected to observe potential reductions in toxin levels.

02

Conditions studied

  • Aflatoxicosis

Keywords

  • probiotic
  • Yoghurt
  • NN20
03

In context

Lead sponsor

This is the only study on the registry with Technical University of Kenya as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:Participants will be recruited from an identified primary school and parental/ legal guardian consent will be required as well as assent from the child. The primary school has been identified with the help of Ministry of agriculture home economics extension officer. The criterion of selecting the primary school is accessibility from Embu ATC where yogurt will be produced and the area which is prone to aflatoxin B1. Children between the ages of 6 and 10 will be enrolled in the study.

-

Exclusion Criteria:Children would be excluded if they are already consuming fermented milk products or are lactose intolerant.

-

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    probiotic yoghurt

    the subject will be given 200ml of yogurt daily for 28 days

    Dietary Supplement: probiotic yoghurt

Interventions

  • Dietary supplementprobiotic yoghurt

    The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya

    Also known as: NN20

06

What researchers measure

Primary outcomes

  1. Aflatoxin M1 in urine

    urine samples will be collected from the subjects every morning before the first meal for a period of 28 days. Test of aflatoxin M1 the bio maker of aflatoxicosis will be carried in the samples.

    Time frame: 28 days

Secondary outcomes

  1. Albumin adduct in blood

    baseline blood samples will be collected before intervetion and at the end of the study. test of albumin adduct in blood will be carried. this a bio maker of aflatoxicosis in blood

    Time frame: 28 days

Other outcomes

  1. microbiota in the stool

    wewill analyze the intestinal microbiota of the children and to determine if consumption of a probiotic yogurt has a significant effect on the microbiota composition.

    Time frame: 28 days

07

Study locations

1 site
  • Embu
    Embu, Embu County, Kenya
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02041026
Lead sponsor
Technical University of Kenya
Collaborators
University of Western Ontario, Canada
Responsible party
Nicholas Nduti (Food scientist, Technical University of Kenya) — Principal investigator
First posted
Jan 20, 2014
Start date
Feb 2014
Primary completion
Apr 2014 (estimated)
Completion
May 2014 (estimated)
Last update
Jan 20, 2014

Study contacts

Nicholas Nduti, PhD (expected)
Contact
nnduti@uwo.ca
+254 7213356
Dr. Gregor Reid, PhD
Contact
gregor@uwo.ca
+151 985 430 22
Gregor Reid, PhD
study director · Lawson health Research Institute- st Joseph hospital London Ontario
Nicholas Nduti, PhD expected
principal investigator · Technical University of Kenya

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion